JP2003527422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003527422A5 JP2003527422A5 JP2001568420A JP2001568420A JP2003527422A5 JP 2003527422 A5 JP2003527422 A5 JP 2003527422A5 JP 2001568420 A JP2001568420 A JP 2001568420A JP 2001568420 A JP2001568420 A JP 2001568420A JP 2003527422 A5 JP2003527422 A5 JP 2003527422A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrochloride
- retinal
- composition
- org
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002207 retinal effect Effects 0.000 description 6
- IPRJDKMLMDPMBH-XFULWGLBSA-N (3r)-n-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-[1]benzothiolo[2,3-c]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.S1C2=CC=CC=C2C(C2)=C1CN[C@H]2C(=O)NCC1=CC=C(OCO2)C2=C1 IPRJDKMLMDPMBH-XFULWGLBSA-N 0.000 description 4
- IGKYREHZJIHPML-UNTBIKODSA-N 2-[4-[[(2r)-3,4-dihydro-2h-chromen-2-yl]methylamino]butyl]-1,1-dioxo-1,2-benzothiazol-3-one;hydron;chloride Chemical compound Cl.O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCNC[C@@H]1OC2=CC=CC=C2CC1 IGKYREHZJIHPML-UNTBIKODSA-N 0.000 description 4
- GGNCUSDIUUCNKE-RSAXXLAASA-N 3-(1,3-benzodioxol-5-yloxy)-n-[[(3s)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine;hydrochloride Chemical compound Cl.C1=C2OCOC2=CC(OCCCNC[C@@H]2OC3=CC=CC=C3OC2)=C1 GGNCUSDIUUCNKE-RSAXXLAASA-N 0.000 description 4
- LTBKOSQVBVYJKW-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-[4-(1,2,4-triazol-1-yl)butyl]-3,6-dihydro-2h-pyridine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(F)=CC=C1C(CC1)=CCN1CCCCN1N=CN=C1 LTBKOSQVBVYJKW-UHFFFAOYSA-N 0.000 description 4
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- -1 Resopitron Chemical compound 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 4
- QDLVYMYXOLGZOD-ZMBIFBSDSA-N [(2r)-3,4-dihydro-2h-chromen-2-yl]methyl-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]azanium;chloride Chemical compound Cl.C1=CC(F)=CC=C1C1=CN=CC(CNC[C@@H]2OC3=CC=CC=C3CC2)=C1 QDLVYMYXOLGZOD-ZMBIFBSDSA-N 0.000 description 4
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 4
- 229960002495 buspirone Drugs 0.000 description 4
- NYSDRDDQELAVKP-SFHVURJKSA-N flesinoxan Chemical compound C([C@@H](O1)CO)OC2=C1C=CC=C2N(CC1)CCN1CCNC(=O)C1=CC=C(F)C=C1 NYSDRDDQELAVKP-SFHVURJKSA-N 0.000 description 4
- 229950003678 flesinoxan Drugs 0.000 description 4
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 description 4
- 229960002053 flibanserin Drugs 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- URMTUEWUIGOJBW-UHFFFAOYSA-N piclozotan Chemical compound ClC1=COC2=CC=CC=C2C(=O)N1CCCCN(CC=1)CCC=1C1=CC=CC=N1 URMTUEWUIGOJBW-UHFFFAOYSA-N 0.000 description 4
- RKZSNTNMEFVBDT-MRVPVSSYSA-N sumanirole Chemical compound C([C@H](C1)NC)C2=CC=CC3=C2N1C(=O)N3 RKZSNTNMEFVBDT-MRVPVSSYSA-N 0.000 description 4
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 4
- 229950000505 tandospirone Drugs 0.000 description 4
- 229960001130 urapidil Drugs 0.000 description 4
- RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical compound Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 description 4
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 4
- 229960000607 ziprasidone Drugs 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 2
- 208000002367 Retinal Perforations Diseases 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 239000003723 serotonin 1A agonist Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 1
- 206010038897 Retinal tear Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19027900P | 2000-03-17 | 2000-03-17 | |
| US60/190,279 | 2000-03-17 | ||
| PCT/US2001/005700 WO2001070222A2 (en) | 2000-03-17 | 2001-02-23 | Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010261857A Division JP2011037901A (ja) | 2000-03-17 | 2010-11-24 | 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物 |
| JP2011108785A Division JP2011153158A (ja) | 2000-03-17 | 2011-05-13 | 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003527422A JP2003527422A (ja) | 2003-09-16 |
| JP2003527422A5 true JP2003527422A5 (https=) | 2007-10-18 |
| JP4789231B2 JP4789231B2 (ja) | 2011-10-12 |
Family
ID=22700682
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001568421A Pending JP2003527423A (ja) | 2000-03-17 | 2001-02-20 | 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物 |
| JP2001568428A Withdrawn JP2003527427A (ja) | 2000-03-17 | 2001-02-23 | 視野損失を抑制するのに有用な５−ｈｔ活性を有する化合物 |
| JP2001568420A Expired - Fee Related JP4789231B2 (ja) | 2000-03-17 | 2001-02-23 | 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物 |
| JP2010261857A Withdrawn JP2011037901A (ja) | 2000-03-17 | 2010-11-24 | 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物 |
| JP2011108785A Withdrawn JP2011153158A (ja) | 2000-03-17 | 2011-05-13 | 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001568421A Pending JP2003527423A (ja) | 2000-03-17 | 2001-02-20 | 緑内障処置用の５−ｈｔ２および５−ｈｔ１ａアゴニスト活性を有する化合物 |
| JP2001568428A Withdrawn JP2003527427A (ja) | 2000-03-17 | 2001-02-23 | 視野損失を抑制するのに有用な５−ｈｔ活性を有する化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010261857A Withdrawn JP2011037901A (ja) | 2000-03-17 | 2010-11-24 | 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物 |
| JP2011108785A Withdrawn JP2011153158A (ja) | 2000-03-17 | 2011-05-13 | 網膜外縁部障害の処置に有用な５−ｈｔ１ａ活性を有する化合物 |
Country Status (18)
| Country | Link |
|---|---|
| EP (3) | EP1263434A1 (https=) |
| JP (5) | JP2003527423A (https=) |
| KR (3) | KR20030016239A (https=) |
| CN (2) | CN1418100A (https=) |
| AR (1) | AR028258A1 (https=) |
| AT (1) | ATE247507T1 (https=) |
| AU (5) | AU2001238552A1 (https=) |
| BR (3) | BR0109193A (https=) |
| CA (3) | CA2400637A1 (https=) |
| DE (1) | DE60100625T2 (https=) |
| DK (1) | DK1263504T3 (https=) |
| ES (1) | ES2204848T3 (https=) |
| MX (3) | MXPA02009071A (https=) |
| PL (1) | PL203709B1 (https=) |
| PT (1) | PT1263504E (https=) |
| TW (1) | TWI268777B (https=) |
| WO (3) | WO2001070223A1 (https=) |
| ZA (1) | ZA200206350B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960579B1 (en) | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
| US20030207890A1 (en) | 2001-02-23 | 2003-11-06 | Collier Robert J | Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| BR0109193A (pt) * | 2000-03-17 | 2003-05-27 | Alcon Inc | Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma |
| TW593302B (en) | 2001-12-20 | 2004-06-21 | Alcon Inc | Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| BR0316775A (pt) | 2002-12-13 | 2005-11-01 | Alcon Inc | Novos análogos de benzopirano e seu uso para o tratamento de glaucoma |
| JP2004262812A (ja) * | 2003-02-28 | 2004-09-24 | Rohto Pharmaceut Co Ltd | 眼圧低下剤 |
| JP4808612B2 (ja) * | 2003-04-25 | 2011-11-02 | 田辺三菱製薬株式会社 | アルキレンジオキシベンゼン誘導体を含む経口投与用組成物 |
| US7476687B2 (en) | 2003-11-26 | 2009-01-13 | Alcon, Inc. | Substituted furo[2,3-g]indazoles for the treatment of glaucoma |
| TW200520760A (en) | 2003-12-15 | 2005-07-01 | Alcon Inc | Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma |
| US7129257B1 (en) | 2003-12-15 | 2006-10-31 | Alcon, Inc. | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma |
| US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| EP2248524A3 (en) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| US7425572B2 (en) | 2004-12-08 | 2008-09-16 | Alcon, Inc. | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
| WO2008117269A2 (en) | 2007-03-28 | 2008-10-02 | Atir Holding S.A. | Heterotri cyciii c compounds as serotonergic and/or dopaminergic agents and uses thereof |
| EP2742936A1 (en) | 2006-05-16 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| WO2008024846A2 (en) * | 2006-08-25 | 2008-02-28 | Allergan, Inc. | Brimonidine and timolol compositions |
| EP2789338A3 (en) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivate and use thereof |
| TW201010727A (en) * | 2008-09-03 | 2010-03-16 | Alcon Res Ltd | Pharmaceutical composition having relatively low ionic strength |
| PH12012500928A1 (en) | 2009-11-09 | 2012-11-26 | Allergan Inc | Compositions and methods for stimulating hair growth |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| CN109602691A (zh) | 2013-02-15 | 2019-04-12 | 阿勒根公司 | 持续药物递送植入物 |
| WO2018064465A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
| CN113784962B (zh) | 2019-02-27 | 2025-04-25 | 加利福尼亚大学董事会 | 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环 |
| AU2020228289B2 (en) | 2019-02-27 | 2026-02-05 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| TW202333668A (zh) | 2021-12-15 | 2023-09-01 | 美商德利克斯醫療公司 | 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途 |
| PL4452267T3 (pl) * | 2021-12-23 | 2025-06-23 | Cilcare Dev | Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02262518A (ja) * | 1989-04-03 | 1990-10-25 | Kaken Pharmaceut Co Ltd | 眼圧調整剤 |
| JP2824863B2 (ja) * | 1989-07-12 | 1998-11-18 | エーザイ株式会社 | α▲下１▼―ブロッカー点眼剤 |
| TW270114B (https=) * | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
| US5521183A (en) * | 1994-08-30 | 1996-05-28 | Allergan | Use of 5-HT ligands as anti-pruritic agents |
| US5998467A (en) * | 1995-10-25 | 1999-12-07 | Mitsubishi Chemical Corporation | Medicine for oculopathy |
| JP3958391B2 (ja) * | 1995-10-25 | 2007-08-15 | 三菱化学株式会社 | 眼疾患用薬剤 |
| WO1998018458A1 (en) * | 1996-10-31 | 1998-05-07 | Alcon Laboratories, Inc. | Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
| BR0109193A (pt) * | 2000-03-17 | 2003-05-27 | Alcon Inc | Compostos com atividade agonista 5-ht2 e 5-ht1a para tratamento do glaucoma |
-
2001
- 2001-02-20 BR BR0109193-0A patent/BR0109193A/pt not_active Application Discontinuation
- 2001-02-20 CA CA002400637A patent/CA2400637A1/en not_active Abandoned
- 2001-02-20 AU AU2001238552A patent/AU2001238552A1/en not_active Abandoned
- 2001-02-20 JP JP2001568421A patent/JP2003527423A/ja active Pending
- 2001-02-20 MX MXPA02009071A patent/MXPA02009071A/es unknown
- 2001-02-20 KR KR1020027012169A patent/KR20030016239A/ko not_active Withdrawn
- 2001-02-20 EP EP01911005A patent/EP1263434A1/en not_active Withdrawn
- 2001-02-20 WO PCT/US2001/005432 patent/WO2001070223A1/en not_active Ceased
- 2001-02-23 KR KR1020027012170A patent/KR100749191B1/ko not_active Expired - Fee Related
- 2001-02-23 MX MXPA02009072A patent/MXPA02009072A/es active IP Right Grant
- 2001-02-23 CA CA2400639A patent/CA2400639C/en not_active Expired - Fee Related
- 2001-02-23 BR BR0109230-8A patent/BR0109230A/pt not_active Application Discontinuation
- 2001-02-23 AU AU2001239836A patent/AU2001239836A1/en not_active Abandoned
- 2001-02-23 WO PCT/US2001/005700 patent/WO2001070222A2/en not_active Ceased
- 2001-02-23 DE DE60100625T patent/DE60100625T2/de not_active Expired - Lifetime
- 2001-02-23 DK DK01918208T patent/DK1263504T3/da active
- 2001-02-23 CN CN01806620A patent/CN1418100A/zh active Pending
- 2001-02-23 EP EP01918208A patent/EP1263504B1/en not_active Expired - Lifetime
- 2001-02-23 CA CA002399985A patent/CA2399985A1/en not_active Abandoned
- 2001-02-23 KR KR1020027012171A patent/KR20030009390A/ko not_active Withdrawn
- 2001-02-23 WO PCT/US2001/005740 patent/WO2001070230A2/en not_active Ceased
- 2001-02-23 EP EP01914447A patent/EP1267878A2/en not_active Withdrawn
- 2001-02-23 AU AU2001245310A patent/AU2001245310B2/en not_active Ceased
- 2001-02-23 ES ES01918208T patent/ES2204848T3/es not_active Expired - Lifetime
- 2001-02-23 CN CNB018067646A patent/CN1198605C/zh not_active Expired - Fee Related
- 2001-02-23 BR BR0109211-1A patent/BR0109211A/pt not_active Application Discontinuation
- 2001-02-23 JP JP2001568428A patent/JP2003527427A/ja not_active Withdrawn
- 2001-02-23 AU AU4531001A patent/AU4531001A/xx active Pending
- 2001-02-23 PT PT01918208T patent/PT1263504E/pt unknown
- 2001-02-23 JP JP2001568420A patent/JP4789231B2/ja not_active Expired - Fee Related
- 2001-02-23 PL PL358306A patent/PL203709B1/pl not_active IP Right Cessation
- 2001-02-23 MX MXPA02009073A patent/MXPA02009073A/es unknown
- 2001-02-23 AT AT01918208T patent/ATE247507T1/de active
- 2001-03-15 AR ARP010101211A patent/AR028258A1/es not_active Application Discontinuation
- 2001-03-16 TW TW090106235A patent/TWI268777B/zh not_active IP Right Cessation
-
2002
- 2002-08-08 ZA ZA200206350A patent/ZA200206350B/en unknown
-
2005
- 2005-06-15 AU AU2005202600A patent/AU2005202600B2/en not_active Ceased
-
2010
- 2010-11-24 JP JP2010261857A patent/JP2011037901A/ja not_active Withdrawn
-
2011
- 2011-05-13 JP JP2011108785A patent/JP2011153158A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003527422A5 (https=) | ||
| WO2001070222A3 (en) | Compounds with 5-ht1a activity useful for treating disorders of the outer retina | |
| Yadav et al. | Glaucoma: Current treatment and impact of advanced drug delivery systems | |
| US11648261B2 (en) | Method of treating, reducing, or alleviating a medical condition in a patient | |
| Romero-Aroca et al. | Laser treatment for diabetic macular edema in the 21st century | |
| RU2005118108A (ru) | Ингибиторы гистондеацетилазы для лечения дегенеративных заболеваний глаз | |
| US20040216749A1 (en) | Vasomodulation during glaucoma surgery | |
| JP5740343B2 (ja) | 水晶体の変化による老眼治療 | |
| JP2006524185A5 (https=) | ||
| TW200302226A (en) | Methods for treating ocular neovascular diseases | |
| AU2009257572A1 (en) | Low dose topiramate/phentermine composition and methods of use thereof | |
| CA2582316A1 (en) | Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases | |
| US20050205101A1 (en) | Combined pharmocological and surgical method and system for the treatment of eye disorders | |
| Üretmen et al. | Comparison of outcomes of viscocanalostomy and phacoviscocanalostomy | |
| EP1752158A4 (en) | PACAP AND ITS DERIVATIVE KORNEANEURITOGENESIS PROMOTER | |
| Arevalo et al. | Macular hole after LASIK | |
| EP1545494A1 (en) | Use of propionyl l-carnitine for the preparation of a medicament for the treatment of glaucoma | |
| RU2380072C1 (ru) | Способ комбинированного лечения первичной открытоугольной глаукомы и катаракты | |
| Arevalo et al. | Simultaneous bilateral ocular decompression retinopathy after trabeculectomy with mitomycin C for uveitic glaucoma | |
| Rao et al. | Timing of retreatment after a partial flap during laser in situ keratomileusis | |
| RU2120265C1 (ru) | Способ реваскуляризации хориоидеи | |
| Smiddy et al. | Simulated treatment of recurrent choroidal neovascularization in primate retina: Comparative histopathologic findings | |
| RU2308923C1 (ru) | Способ лечения птеригиума | |
| Pavithran et al. | Customised acrylic nasal stents following recanalisation of modified Young's procedure | |
| Javed | Phacoemulsification under Topical Anesthesia Alone Versus Topical Anesthesia with Subconjunctival |